Novo Nordisk Announces New Retrospective Real-world Evidence For Type 2 Diabetes Showing Semaglutide Injection 2 Mg Was Associated With A Statistically Significant 6% Lower Risk Of Major Adverse Cardiovascular Events, Than Those Who Switched To... — Dernières actualités